NICOX TO BEGIN TWO TRIALS OF NCX 4016 FOR DIABETES
NicOx has announced it will move NCX 4016 forward in development as an insulin-sensitizing agent for the treatment of Type 2 diabetes. The company expects to initiate two Phase II studies, which will have the goal of confirming the mechanism of action and demonstrating clinical benefit of the drug.
The first study will be a single-center, crossover trial, designed to confirm the mechanism of action of NCX 4016 as an insulin-sensitizing agent using a hyperinsulinemic euglycemic clamp. The second trial will be a placebo and active controlled, double-blind, parallel study, aiming to demonstrate a clinical benefit for NCX 4016 through the measurement of HbA1c (glycosylated hemoglobin, the standard test for glycemic control in diabetics) and blood glucose in the fasting state and after meals.